A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis
- 1 August 1997
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 49 (2) , 626-628
- https://doi.org/10.1212/wnl.49.2.626
Abstract
Tumor necrosis factor alpha (TNFα) expression in enhanced in patients with active MS and other inflammatory disease. A guanine-to-adenine polymorphism at position -308 of the TNFα promoter region (the TNF2 allele) is associated with increased TNFα expression. We evaluated 110 MS patients derived from an Olmsted County, MN, prevalence study. Three other patient cohorts (autoimmune, serious infectious illness, and other neurologic diseases) and matched controls were derived from a Mayo Clinic DNA bank. We used polymerase chain reaction amplification of specific alleles to screen for the TNF2 allele and to determine zygosity. We found one homozygote and 29 heterozygotes in the MS patients. There was no association between the presence of the TNF2 allele and MS or the other disease categories by matched-pair and group analyses.Keywords
This publication has 4 references indexed in Scilit:
- Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosisNeurology, 1997
- Corticotropin-releasing hormone is involved in conditioned stimulus-induced reduction of natural killer cell activity but not in conditioned alterations in cytokine production or proliferation responsesJournal of Neuroimmunology, 1995
- The role of genetic factors in multiple sclerosis susceptibilityJournal of Neuroimmunology, 1994
- Radioastronomers hope for world observatoryNature, 1994